Table 2.
Logistic regression of likelihood of bevacizumab (Bev) use among CRC patients who were 65 years or older and treated with chemotherapy.a
| Odds ratio |
95% Confidence interval |
p | ||
|---|---|---|---|---|
| Age groups | ||||
| 65–69 years (reference) | ||||
| 80 years or above | 0.64 | 0.57 | 0.73 | <0.0001 |
| Cancer registry site | ||||
| New Mexico | 1.60 | 1.16 | 2.19 | 0.004 |
| Georgia | 1.55 | 1.30 | 1.86 | <0.0001 |
| Seattle metro area | 1.42 | 1.12 | 1.79 | 0.003 |
| Louisiana | 1.27 | 1.03 | 1.57 | 0.029 |
| Detroit metro area | 1.23 | 1.01 | 1.50 | 0.041 |
| New Jersey (reference) | ||||
| Marital status | ||||
| Married | 1.11 | 1.01 | 1.21 | 0.033 |
| Other (reference) | ||||
| Income | ||||
| Q1 (reference) | ||||
| Q4 | 1.20 | 1.03 | 1.40 | 0.021 |
| CRC stage at diagnosis | ||||
| I–III (reference) | ||||
| IV | 1.78 | 1.63 | 1.95 | <0.0001 |
| Co-morbid conditions | ||||
| CM/CHF | 0.82 | 0.70 | 0.95 | 0.009 |
| Arrhythmic disorder | 0.85 | 0.75 | 0.96 | 0.009 |
| Modified Charlson index | 0.93 | 0.89 | 0.98 | 0.007 |
Q1–Q4: quartile 1–quartile 4 from lowest to highest; CRC: colorectal cancer; CM/CHF: cardiomyopathy or congestive heart failure.
a
Variables with significant results are listed in the table. The model also adjusted for the effects of sex, race/ethnicity, other registry sites, education, other co-morbid conditions including gastrointestinal perforation, arterial thromboembolism, and other cardiac conditions.